Bristol Myers Squibb Co (BMY)
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers products for oncology, hematology, immunology, cardiovascular, and neuroscience indications. Its products include Opdivo for anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumors; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Opdualag to treat unresectable or metastatic melanoma; and Camzyos for the treatment of symptomatic obstructive HCM. The company also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu to treat moderate-to-severe plaque psoriasis; Krazati for the treatment of KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for the reduction of risk of stroke/systemic embolism and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug for multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane to treat breast cancer. Further, the company provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC, as well as NSCLC and pancreatic cancer. It sells its products to wholesalers, distributors, specialty pharmacies, retailers, hospitals, clinics, and government agencies. The company has a strategic collaboration with Arcus Biosciences, Inc. to develop a treatment regimen that delivers tumor control in kidney cancer. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
- Ticker
- BMY
- Exchange
- NYSE
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Market cap
- $128.57B
- 52-week range
- $45.27 - $68.64
Valuation
- Share price
- $62.93 (close of Nov 16, 2026)
- P/E (TTM)
- 13.89x
- Price to book
- 5.49x
- Price to free cash flow
- 13.85x
- Enterprise value
- $160.79B
- Book value per share
- $11.46
Price performance
| Period | Change |
|---|---|
| 1 day | -0.79% |
| 5 days | +1.27% |
| 1 month | +5.32% |
| 3 months | -1.41% |
| 6 months | +10.40% |
| Year to date | +16.67% |
| 1 year | +34.90% |
| 3 years | +23.78% |
| 5 years | +6.48% |
| 10 years | +11.98% |
| All time | +3,271.78% |
Short interest
- As of
- Oct 30, 2026
- Short % of float
- 2.30%
- Shares short
- 46.85M
- Days to cover
- 4.24
- Change since prior report
- -6.20%
- Source
- FINRA consolidated short interest
Members of Congress who disclosed BMY trades
Julie Johnson · Gilbert Ray Cisneros · Julia Letlow · Virginia Foxx · Alan Armstrong · Greg Landsman · Jefferson Shreve · Mike Kelly · Tommy Tuberville · Val Hoyle
Super investors holding BMY
Richard Pzena (Pzena Investment Management) · Ken Griffin (Citadel) · John Rogers (Ariel Investments LLC) · Kahn Brothers (Kahn Brothers Group) · Bill Miller (Miller Value Partners, LLC) · Hillman Capital (Hillman Capital Management, Inc) · Dodge & Cox (Dodge & Cox Funds) · Tweedy Browne (Tweedy Browne Company LLC) · Mairs & Power (Mairs & Power Inc)
Profitability and growth
- Return on equity
- 38.12%
- Return on invested capital
- 13.63%*
- Return on assets
- 7.83%
- Return on capital employed
- 16.84%*
- Gross margin
- 71.08%
- Net margin
- 14.64%
- EBITDA margin
- 31.60%
- Revenue growth
- -0.22%
- Free cash flow growth
- -7.87%
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash flow and balance sheet
- Free cash flow yield (TTM)
- 7.22%
- Current ratio
- 1.59x
- Net debt to EBITDA
- 2.04x
Latest reported year
- Period end
- Dec 31, 2025
- Fiscal year
- 2025
- Revenue
- $48.19B
- Cost of revenue
- $13.94B
- Gross profit
- $34.26B
- EBITDA
- $15.23B
- Net income
- $7.05B
- Earnings per share
- $3.47
- Research and development
- $9.95B
- Interest expense
- $1.89B
- Shares outstanding
- 2.03B
Income statement by year
| Period end | Revenue | Gross profit | Net income | EPS |
|---|---|---|---|---|
| 2025-12-31 | $48.19B | $34.26B | $7.05B | $3.47 |
| 2024-12-31 | $48.30B | $34.33B | -$8.95B | -$4.41 |
| 2023-12-31 | $45.01B | $34.31B | $8.03B | $3.88 |
| 2022-12-31 | $46.16B | $36.02B | $6.33B | $2.97 |
| 2021-12-31 | $46.38B | $36.45B | $6.99B | $3.15 |
| 2020-12-31 | $42.52B | $30.75B | -$9.02B | -$3.99 |
| 2019-12-31 | $26.14B | $18.07B | $3.44B | $2.02 |
| 2018-12-31 | $22.56B | $16.09B | $4.92B | $3.01 |
| 2017-12-31 | $20.78B | $14.68B | $1.01B | $0.61 |
| 2016-12-31 | $19.43B | $14.48B | $4.46B | $2.67 |
Margins and returns by year
| Period end | Gross margin | Net margin | Return on equity | Return on capital |
|---|---|---|---|---|
| 2025-12-31 | 71.08% | 14.64% | 38.12% | 13.63%* |
| 2024-12-31 | 71.08% | -18.53% | -54.60% | -9.52%* |
| 2023-12-31 | 76.24% | 17.83% | 27.22% | 12.98%* |
| 2022-12-31 | 78.04% | 13.71% | 20.33% | 10.55%* |
| 2021-12-31 | 78.57% | 15.08% | 19.42% | 10.23%* |
| 2020-12-31 | 72.31% | -21.20% | -23.80% | -6.09%* |
| 2019-12-31 | 69.10% | 13.15% | 6.65% | 4.15%* |
| 2018-12-31 | 71.34% | 21.81% | 34.83% | 23.89%* |
| 2017-12-31 | 70.67% | 4.85% | 8.50% | 13.45%* |
| 2016-12-31 | 74.54% | 22.94% | 27.26% | 20.27%* |
* Estimated EBIT: pre-tax income + net interest. This company reports no operating income line.
Cash and debt by year
| Period end | Cash | Debt |
|---|---|---|
| 2025-12-31 | $10.67B | $42.85B |
| 2024-12-31 | $10.86B | $47.60B |
| 2023-12-31 | $12.28B | $36.65B |
| 2022-12-31 | $9.25B | $35.06B |
| 2021-12-31 | $13.98B | $39.60B |
| 2020-12-31 | $14.55B | $48.34B |
| 2019-12-31 | $12.35B | $43.39B |
| 2018-12-31 | $6.91B | $5.65B |
| 2017-12-31 | $5.42B | $6.97B |
| 2016-12-31 | $4.24B | $5.72B |
Free cash flow by year
| Period end | Free cash flow | Stock-based compensation |
|---|---|---|
| 2025-12-31 | $12.85B | $553.00M |
| 2024-12-31 | $13.94B | $507.00M |
| 2023-12-31 | $12.65B | $518.00M |
| 2022-12-31 | $11.95B | $457.00M |
| 2021-12-31 | $15.23B | $583.00M |
| 2020-12-31 | $13.30B | $779.00M |
| 2019-12-31 | $7.37B | $441.00M |
| 2018-12-31 | $6.12B | $221.00M |
| 2017-12-31 | $4.22B | $199.00M |
| 2016-12-31 | $1.84B | $205.00M |
Dividend history
- Most recent payment
- Oct 2, 2026
- Paid in the last twelve months
- $2.52
| Payment date | Dividend per share |
|---|---|
| 2026-10-02 | $0.63 |
| 2026-07-02 | $0.63 |
| 2026-04-02 | $0.63 |
| 2026-01-02 | $0.63 |
| 2025-10-03 | $0.62 |
| 2025-07-03 | $0.62 |
| 2025-04-04 | $0.62 |
| 2025-01-03 | $0.62 |
Investor relations
Past earnings dates
| Reported | Fiscal period | EPS estimate |
|---|---|---|
| 2026-10-29 | Sep 2026 | $1.21 |
| 2026-07-30 | Jun 2026 | $1.59 |
| 2026-04-30 | Mar 2026 | $1.44 |
| 2026-02-05 | Dec 2025 | $1.15 |
| 2025-10-30 | Sep 2025 | $1.48 |
| 2025-07-31 | Jun 2025 | $1.07 |
| 2025-04-24 | Mar 2025 | $1.51 |
| 2025-02-06 | Dec 2024 | $1.46 |
Filings and sources
- Company website
- bms.com
- SEC filings
- 10-K, 10-Q and 8-K on EDGAR
- Earnings calendar
- All upcoming reports
Similar companies
Biogen Inc. (BIIB) · Pfizer Inc (PFE) · Organon & Co. (OGN) · Gilead Sciences, Inc. (GILD) · GSK plc (GSK) · Amgen Inc (AMGN) · Novo Nordisk A S (NVO) · AstraZeneca plc (AZN)
Understanding these figures
Price-to-earnings ratio · Short interest · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart
Explore
Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades